News

Business Insider6y
Catalent Invests Over $27 Million to Commercialize Zydis® Ultra, a Next Generation Oral Disintegrating Tablet - Markets Insider
SOMERSET, N.J., Mar. 7, 2019 /PRNewswire-PRWeb/ -- Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and ...
Yahoo Finance2y
Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology - Yahoo Finance
Catalent, Inc. CTLT recently executed a development and license agreement with Ethicann Pharmaceuticals Inc. to develop Ethicann’s clinical drug pipeline using its proprietary Zydis orally ...
Nasdaq1y
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and ... - Nasdaq
Under the terms of the agreement, Melt Pharmaceuticals will utilize Catalent’ s proprietary Zydis ® orally disintegrating tablet fast-dissolve technology with MELT-300, a sublingual, needle ...
Medindia3y
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve Zydis® Formulation for Cannabidiol as an Anesthesia Premedication
SOMERSET, N.J., July 13, 2021 /PRNewswire-PRWeb/ -- Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and ...
Healio1y
MindMed secures Zydis oral tablet technology for LSD-based anxiety treatment - Healio
Calling Zydis “very versatile and effective in developing easy-to-administer dose forms for innovators,” Tom Hawkeswood, president and division head of pharma product delivery at Catalent ...
Medindia6y
Catalent Invests Over $27 Million to Commercialize Zydis® Ultra, a Next Generation Oral Disintegrating Tablet - Medindia
SOMERSET, N.J., Mar. 7, 2019 /PRNewswire-PRWeb/ -- Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and ...
Yahoo Finance2y
Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology - Yahoo Finance
Catalent, Inc. CTLT recently executed a development and license agreement with Ethicann Pharmaceuticals Inc. to develop Ethicann’s clinical drug pipeline using its proprietary Zydis orally ...